Literature DB >> 30785763

New Treatment Approaches and Prognostic Biomarkers for Advanced Chronic Obstructive Pulmonary Disease and Potential Associated Cardiovascular Risks.

Omar Khorfan1,2, Samer Alsamman1,2, Hawazin Abbas1,2, Abdulghani Sankari1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30785763      PMCID： PMC6444652          DOI： 10.1164/rccm.201804-0659RR

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  15 in total

1.  Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.

Authors:  Jørgen Vestbo; Alberto Papi; Massimo Corradi; Viktor Blazhko; Isabella Montagna; Catherine Francisco; Géraldine Cohuet; Stefano Vezzoli; Mario Scuri; Dave Singh
Journal:  Lancet       Date:  2017-04-03       Impact factor: 79.321

2.  Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.

Authors:  Meng-Ting Wang; Jun-Ting Liou; Chen Wei Lin; Chen-Liang Tsai; Yun-Han Wang; Yu-Juei Hsu; Jyun-Heng Lai
Journal:  JAMA Intern Med       Date:  2018-02-01       Impact factor: 21.873

3.  FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.

Authors:  David A Lipson; Helen Barnacle; Ruby Birk; Noushin Brealey; Nicholas Locantore; David A Lomas; Andrea Ludwig-Sengpiel; Rajat Mohindra; Maggie Tabberer; Chang-Qing Zhu; Steven J Pascoe
Journal:  Am J Respir Crit Care Med       Date:  2017-08-15       Impact factor: 21.405

4.  Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study.

Authors:  Dave Singh; Lisa Edwards; Ruth Tal-Singer; Stephen Rennard
Journal:  Respir Res       Date:  2010-06-15

5.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Authors:  Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

6.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Authors:  Jadwiga A Wedzicha; Donald Banerji; Kenneth R Chapman; Jørgen Vestbo; Nicolas Roche; R Timothy Ayers; Chau Thach; Robert Fogel; Francesco Patalano; Claus F Vogelmeier
Journal:  N Engl J Med       Date:  2016-05-15       Impact factor: 91.245

Review 7.  Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment.

Authors:  R Wood-Baker; B Cochrane; M T Naughton
Journal:  Intern Med J       Date:  2009-10-22       Impact factor: 2.048

8.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

Authors:  Mona Bafadhel; Susan McKenna; Sarah Terry; Vijay Mistry; Carlene Reid; Pranabashis Haldar; Margaret McCormick; Koirobi Haldar; Tatiana Kebadze; Annelyse Duvoix; Kerstin Lindblad; Hemu Patel; Paul Rugman; Paul Dodson; Martin Jenkins; Michael Saunders; Paul Newbold; Ruth H Green; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling
Journal:  Am J Respir Crit Care Med       Date:  2011-09-15       Impact factor: 21.405

9.  Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.

Authors:  Annette T Hastie; Fernando J Martinez; Jeffrey L Curtis; Claire M Doerschuk; Nadia N Hansel; Stephanie Christenson; Nirupama Putcha; Victor E Ortega; Xingnan Li; R Graham Barr; Elizabeth E Carretta; David J Couper; Christopher B Cooper; Eric A Hoffman; Richard E Kanner; Eric Kleerup; Wanda K O'Neal; Richard Paine; Stephen P Peters; Neil E Alexis; Prescott G Woodruff; MeiLan K Han; Deborah A Meyers; Eugene R Bleecker
Journal:  Lancet Respir Med       Date:  2017-11-13       Impact factor: 30.700

Review 10.  How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Authors:  Kai M Beeh; Pierre-Regis Burgel; Frits M E Franssen; Jose Luis Lopez-Campos; Stelios Loukides; John R Hurst; Matjaž Fležar; Charlotte Suppli Ulrik; Fabiano Di Marco; Daiana Stolz; Arschang Valipour; Brian Casserly; Björn Ställberg; Konstantinos Kostikas; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.